September 14, 2020 -- Thermo Fisher Scientific announced new collaborations for clinical biomarker discovery among the Thermo Fisher Precision Medicine Science Center, AstraZeneca, and the University of Nebraska Medical Center.
The alliances strengthen the center's mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation.
Through the collaborations, ongoing and planned studies with both groups will utilize standardized plasma protein profiling workflows, including Thermo Fisher's ultrahigh-throughput plasma protein profiling workflow for biomarker discovery, for a range of conditions. Other standardized workflows consist of automated sample preparation for untargeted and targeted methods in combination with Thermo's Orbitrap Exploris 480 and Exploris 240 mass spectrometers.
Using advanced sample processing and downstream analytical applications, the collaboration with AstraZeneca aims to establish a model for clinical proteomics to help identify new drug targets and biomarkers.
Researchers at the University of Nebraska Medical Center are interested in filling research gaps between sample analysis and clinical applications.